Modulation of Activity of the Ubiquitin-Proteasome System for Therapy of Socially Significant Diseases

Abstract The ubiquitin–proteasome system (UPS) plays a crucial role in the degradation of intracellular proteins. UPS consists of proteasomes, multisubunit protein complexes responsible for proteolysis. Their main function is to maintain proteostasis. In addition, proteasomes participate in various regulatory and signaling processes, such as controlling gene expression and intercellular communication. Constitutive proteasomes make up the majority of the proteasome pool in mammalian cells. However, alternative forms of proteasomes exist that are formed by incorporating catalytic immune subunits instead of the constitutive β1, β2, and β5. These immune proteasomes are induced by pro-inflammatory cytokines, such as interferon gamma (IFN-γ) and tumor necrosis factor (TNF). Immune proteasomes have altered proteolytic activity and produce peptides more efficiently than constitutive proteasomes, which are suitable for presentation by MHC class I molecules on the cell membrane. This determines their role in the immune response. As a result, the expression levels of genes encoding the catalytic subunits of proteasomes and their activity can be used as prognostic factors for oncological, autoimmune, and neurodegenerative diseases. The key role of proteasomes in various aspects of cell metabolism makes them promising therapeutic targets. Over the past 15 years, a number of proteasome inhibitors, bortezomib (Velcade), carfilzomib (Kyprolis), and ixazomib (Ninlaro), were approved for clinical use as anticancer drugs. These drugs have a broad spectrum of action and inhibit various forms of proteasomes. Additionally, specific inhibitors for immune proteasomes are under development and undergoing clinical trials. However, as with pan-specific inhibitors, there are some disadvantages to consider, such as toxicity and the potential for drug resistance. Therefore, the search for new agents that specifically target gene expression and various forms of proteasome activity is of great interest. Furthermore, the specific roles of alternative forms of proteasome, as well as their localization in cells and interactions with other proteins remain to be elucidated. This review describes the main forms and functions of proteases, the mechanisms regulating the expression of genes encoding their subunits, the variety of activators, and the characteristics of UPS function in various pathological conditions.

Authors

Institutions

Publication Details

Journal
Molecular Biology
Published
2026-11-18
DOI
https://doi.org/10.1134/s002689332660649x
Primary Topic
Ubiquitin and proteasome pathways
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Modulation of Activity of the Ubiquitin-Proteasome System for Therapy of Socially Significant Diseases

В. Л. Карпов, Alexander V. Burov, Alexey V. Morozov
Molecular Biology
Ubiquitin and proteasome pathways
article

Modulation of Activity of the Ubiquitin-Proteasome System for Therapy of Socially Significant Diseases

В. Л. Карпов, Alexander V. Burov, Alexey V. Morozov
article en

Abstract

Abstract The ubiquitin–proteasome system (UPS) plays a crucial role in the degradation of intracellular proteins. UPS consists of proteasomes, multisubunit protein complexes responsible for proteolysis. Their main function is to maintain proteostasis. In addition, proteasomes participate in various regulatory and signaling processes, such as controlling gene expression and intercellular communication. Constitutive proteasomes make up the majority of the proteasome pool in mammalian cells. However, alternative forms of proteasomes exist that are formed by incorporating catalytic immune subunits instead of the constitutive β1, β2, and β5. These immune proteasomes are induced by pro-inflammatory cytokines, such as interferon gamma (IFN-γ) and tumor necrosis factor (TNF). Immune proteasomes have altered proteolytic activity and produce peptides more efficiently than constitutive proteasomes, which are suitable for presentation by MHC class I molecules on the cell membrane. This determines their role in the immune response. As a result, the expression levels of genes encoding the catalytic subunits of proteasomes and their activity can be used as prognostic factors for oncological, autoimmune, and neurodegenerative diseases. The key role of proteasomes in various aspects of cell metabolism makes them promising therapeutic targets. Over the past 15 years, a number of proteasome inhibitors, bortezomib (Velcade), carfilzomib (Kyprolis), and ixazomib (Ninlaro), were approved for clinical use as anticancer drugs. These drugs have a broad spectrum of action and inhibit various forms of proteasomes. Additionally, specific inhibitors for immune proteasomes are under development and undergoing clinical trials. However, as with pan-specific inhibitors, there are some disadvantages to consider, such as toxicity and the potential for drug resistance. Therefore, the search for new agents that specifically target gene expression and various forms of proteasome activity is of great interest. Furthermore, the specific roles of alternative forms of proteasome, as well as their localization in cells and interactions with other proteins remain to be elucidated. This review describes the main forms and functions of proteases, the mechanisms regulating the expression of genes encoding their subunits, the variety of activators, and the characteristics of UPS function in various pathological conditions.

Molecular BiologyVol. 60(6)
Engelhardt Institute of Molecular Biology (RU), Russian Academy of Sciences (RU)
Russian Science Foundation
Good health and well-being
Ubiquitin and proteasome pathways
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon